Dacomitinib Nitroso
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Dacomitinib is used to treat non-small cell lung cancer that has spread (metastatic) with an epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation gene. Your doctor will use a test to check for the mutation before you receive this medicine.Dacomitinib Nitroso is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Dacomitinib Nitroso CAS NO:NA chemically represented as (E)-N-(4-((3-Chloro-4-fluorophenyl)(nitroso)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide . Synchemia is the leading manufacturing and exporter of Dacomitinib Nitroso . We supply Dacomitinib Nitroso with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0142900 |
| CAS No | NA |
| Mol.F. | C20H24N8O7 |
| Mol.Wt. | 488.46 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142901 |
| CAS No | 29291-35-8 |
| Mol.F. | C19H18N8O7 |
| Mol.Wt. | 470.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142902 |
| CAS No | 77313-99-6 |
| Mol.F. | C19H22N8O7 |
| Mol.Wt. | 474.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142903 |
| CAS No | NA |
| Mol.F. | C7H4N6O4 |
| Mol.Wt. | 236.15 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142904 |
| CAS No | NA |
| Mol.F. | C19H18N8O7 |
| Mol.Wt. | 470.40 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142905 |
| CAS No | NA |
| Mol.F. | C21H21N5O4 |
| Mol.Wt. | 407.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142906 |
| CAS No | NA |
| Mol.F. | C21H20N4O5 |
| Mol.Wt. | 408.41 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142907 |
| CAS No | NA |
| Mol.F. | C24H23N5O5 |
| Mol.Wt. | 461.48 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142908 |
| CAS No | NA |
| Mol.F. | C19H17N5O4 |
| Mol.Wt. | 379.38 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142909 |
| CAS No | NA |
| Mol.F. | C21H23N5O6 |
| Mol.Wt. | 441.44 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142910 |
| CAS No | NA |
| Mol.F. | C21H23N5O5 |
| Mol.Wt. | 425.45 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142911 |
| CAS No | NA |
| Mol.F. | C21H21N5O5 |
| Mol.Wt. | 423.43g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142912 |
| CAS No | NA |
| Mol.F. | C19H16N4O5 |
| Mol.Wt. | 380.36 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142913 |
| CAS No | NA |
| Mol.F. | C21H23N5O5 |
| Mol.Wt. | 425.45 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142914 |
| CAS No | NA |
| Mol.F. | C22H23N5O4 |
| Mol.Wt. | 421.46 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142915 |
| CAS No | NA |
| Mol.F. | C20H19N5O4 |
| Mol.Wt. | 393.40 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |